Suboptimal Inhibition of Platelet Cyclooxygenase 1 by Aspirin in Systemic Lupus Erythematosus: Association With Metabolic Syndrome

• Published in: Arthritis care & research (2010) Vol. 66; no. 2; pp. 285 - 292
• Main Authors: Kawai, Vivian K., Avalos, Ingrid, Oeser, Annette, Oates, John A., Milne, Ginger L., Solus, Joseph F., Chung, Cecilia P., Stein, C. Michael
• Format: Journal Article
• Language: English
• Published: United States 01.02.2014
• Subjects: Adult; Aspirin - therapeutic use; Biomarkers - blood; Blood Platelets - drug effects; Blood Platelets - enzymology; C-Reactive Protein - metabolism; Chi-Square Distribution; Cyclooxygenase 1 - blood; Cyclooxygenase Inhibitors - therapeutic use; Female; Humans; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - drug therapy; Lupus Erythematosus, Systemic - enzymology; Male; Metabolic Syndrome - blood; Metabolic Syndrome - complications; Middle Aged; Obesity - complications; Prospective Studies; Thromboxane B2 - blood; Time Factors; Treatment Outcome
• ISSN: 2151-464X; 2151-4658; 2151-4658
• DOI: 10.1002/acr.22169

Objective Low‐dose aspirin prevents platelet aggregation by suppressing thromboxane A2 (TXA2) synthesis. However, in some individuals TXA2 suppression by aspirin is impaired, indicating suboptimal inhibition of platelet cyclooxygenase 1 (COX‐1) by aspirin. Because patients with systemic lupus erythe...